Literature DB >> 9847387

Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity.

S P Bour1, C Aberham, C Perrin, K Strebel.   

Abstract

In addition to its role in receptor binding, the envelope glycoprotein of certain human immunodeficiency virus type 2 (HIV-2) isolates, including ROD10, exhibits a biological activity that enhances the release of HIV-2, HIV-1, and simian immunodeficiency virus particles from infected cells. The present study aims at better defining the functional domains involved in this biological activity. To this end, we have characterized the envelope protein of the ROD14 isolate of HIV-2, which, despite 95% homology with the ROD10 envelope at the amino acid level, is unable to enhance viral particle release. Site-directed mutagenesis showed that the presence of a truncation in the cytoplasmic tail of the ROD14 envelope was not responsible for the lack of activity, as previously reported for the HIV-2 ST isolate (G. D. Ritter, Jr., G. Yamshchikov, S. J. Cohen, and M. J. Mulligan, J. Virol. 70:2669-2673, 1996). Similarly, several modifications of the length of the ROD10 envelope cytoplasmic tail did not impair its ability to enhance particle release, suggesting that, in the case of the HIV-2 ROD isolate, particle release activity is not regulated by the length of the cytoplasmic tail.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9847387      PMCID: PMC103888     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein.

Authors:  K Strebel; T Klimkait; F Maldarelli; M A Martin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

2.  Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.

Authors:  M J Mulligan; G V Yamshchikov; G D Ritter; F Gao; M J Jin; C D Nail; C P Spies; B H Hahn; R W Compans
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

3.  Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac.

Authors:  Y M Naidu; H W Kestler; Y Li; C V Butler; D P Silva; D K Schmidt; C D Troup; P K Sehgal; P Sonigo; M D Daniel
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

4.  Molecular characterization of an attenuated human immunodeficiency virus type 2 isolate.

Authors:  P Kumar; H X Hui; J C Kappes; B S Haggarty; J A Hoxie; S K Arya; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.

Authors:  H G Göttlinger; T Dorfman; E A Cohen; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

6.  The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?

Authors:  S Bour; U Schubert; K Peden; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

7.  The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.

Authors:  U Schubert; S Bour; A V Ferrer-Montiel; M Montal; F Maldarell; K Strebel
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain.

Authors:  S W Barnett; M Quiroga; A Werner; D Dina; J A Levy
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

9.  Isolation and characterization of HIV-2 from an AIDS patient in Ghana.

Authors:  K Ishikawa; H Tsujimoto; M Nakai; J A Mingle; M Osei-Kwasi; S E Aggrey; V B Nettey; S N Afoakwa; M Fukasawa; T Kodama
Journal:  AIDS       Date:  1988-10       Impact factor: 4.177

10.  Both virus and host components are important for the manifestation of a Nef- phenotype in HIV-1 and HIV-2.

Authors:  M A Ryan-Graham; K W Peden
Journal:  Virology       Date:  1995-10-20       Impact factor: 3.616

View more
  13 in total

1.  Expression, purification, and activities of full-length and truncated versions of the integral membrane protein Vpu from HIV-1.

Authors:  Che Ma; Francesca M Marassi; David H Jones; Suzana K Straus; Stephan Bour; Klaus Strebel; Ulrich Schubert; Myrta Oblatt-Montal; Mauricio Montal; Stanley J Opella
Journal:  Protein Sci       Date:  2002-03       Impact factor: 6.725

2.  Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release.

Authors:  Beth Noble; Paolo Abada; Juan Nunez-Iglesias; Paula M Cannon
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Enhanced antagonism of BST-2 by a neurovirulent SIV envelope.

Authors:  Kenta Matsuda; Chia-Yen Chen; Sonya Whitted; Elena Chertova; David J Roser; Fan Wu; Ronald J Plishka; Ilnour Ourmanov; Alicia Buckler-White; Jeffrey D Lifson; Klaus Strebel; Vanessa M Hirsch
Journal:  J Clin Invest       Date:  2016-05-09       Impact factor: 14.808

4.  Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.

Authors:  Paolo Abada; Beth Noble; Paula M Cannon
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 5.  HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms.

Authors:  Amy Andrew; Klaus Strebel
Journal:  Mol Aspects Med       Date:  2010-09-19

Review 6.  The cytoplasmic tail of retroviral envelope glycoproteins.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Prog Mol Biol Transl Sci       Date:  2014-12-01       Impact factor: 3.622

7.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

8.  Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env.

Authors:  U Schubert; S Bour; R L Willey; K Strebel
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  The HERV-K human endogenous retrovirus envelope protein antagonizes Tetherin antiviral activity.

Authors:  Cécile Lemaître; Francis Harper; Gérard Pierron; Thierry Heidmann; Marie Dewannieux
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

Review 10.  Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction.

Authors:  Anna Le Tortorec; Suzanne Willey; Stuart J D Neil
Journal:  Viruses       Date:  2011-05-06       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.